Table 4.
Adverse events (grade III/IV)
| Variables | New priming regimens – AML (N=44) | Conventional priming regimens – AML (N=77) | P-value | New priming regimens – MDS (N=36) | Conventional priming regimens – MDS (N=52) | P-value |
|---|---|---|---|---|---|---|
| Leukopenia | 39 (88.6%) | 45 (58.4%) | 0.001 | 32 (88.9%) | 29 (55.8%) | 0.001 |
| Anemia | 36 (81.8%) | 49 (63.6%) | 0.035 | 32 (88.9%) | 32 (61.5%) | 0.005 |
| Thrombocytopenia | 40 (90.9%) | 53 (68.8%) | 0.006 | 31 (86.1%) | 33 (63.5%) | 0.019 |
| Time to reach >20×109/L (days) | 14 (7–21) | 8 (6–12) | 11 (8–18) | 7 (5–11) | ||
| Neutropenia | 36 (81.8%) | 45 (58.4%) | 0.009 | 29 (80.6%) | 28 (53.9%) | 0.010 |
| Time to reach >0.5×109/L (days) | 17 (8–26) | 9 (5–14) | 14 (6–21) | 8 (6–13) | ||
| Nausea, vomiting | 6 (13.6%) | 8 (10.4%) | 0.591 | 4 (11.1%) | 5 (9.6%) | 1.000 |
| Liver dysfunction | 2 (4.5%) | 1 (1.3%) | 0.619 | 1 (2.8%) | 1 (1.9%) | 1.000 |
| Kidney dysfunction | 1 (2.3%) | 0 | 0.776 | 0 | 0 | – |
| Alopecia | 3 (6.8%) | 1 (1.3%) | 0.269 | 1 (2.8%) | 0 | 0.852 |
| Cardiac injury | 0 | 0 | – | 0 | 0 | – |
| Oral ulcer | 10 (22.7%) | 15 (19.5%) | 0.671 | 6 (16.7%) | 7 (13.5%) | 0.677 |
| Neutropenic fever | 25 (56.8%) | 36 (46.8%) | 0.287 | 20 (55.6%) | 25 (48.1%) | 0.490 |
| RBC transfusion (patients) | 40 (90.9%) | 55 (71.4%) | 0.012 | 34 (94.4%) | 35 (67.3%) | 0.003 |
| Cell cycle | 38 (86.4%) | 51 (66.2%) | 0.016 | 33 (91.7%) | 33 (63.5%) | 0.003 |
| PLT transfusion (patients) | 41 (93.2%) | 54 (70.1%) | 0.003 | 33 (91.7%) | 35 (67.3%) | 0.007 |
| Cell cycle | 40 (90.9%) | 52 (67.5%) | 0.004 | 30 (83.3%) | 31 (59.6%) | 0.018 |
| Antibiotic use (patients) | 39 (88.6%) | 56 (72.7%) | 0.040 | 28 (77.8%) | 31 (59.6%) | 0.075 |
| Cell cycle | 34 (77.3%) | 45 (58.4%) | 0.091 | 25 (69.4%) | 28 (53.8%) | 0.142 |
Note: Data in bold indicates statistical significance (P<0.05).
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; RBC, red blood cell; PLT, platelet.